H ypoglycemia currently constitutes a significant limitation in the treatment of IDDM. This arises from the current attempts to more aggressively control blood glucose levels in diabetic patients. While the efficacy of such treatment in ameliorating longterm complications has been demonstrated (1) , individuals undergoing such therapy are exposed to a threefold greater risk for severe hypoglycemic episodes (2) . The susceptibility of IDDM patients to hypoglycemia can in part be attributed to their defective counterregulatory hormonal response, which fails to stimulate adequate glucose production (3,4)-This defect has been shown to be specific for glucose, as the hormonal response to other stimuli is apparently normal in diabetic subjects (4) . Such specificity suggests a defect in the afferent limb of glucose counterregulation, i.e., glucose sensing.
Efforts to elucidate the nature of this defect have in part been constrained by our lack of understanding regarding the locus for glycemic detection. Traditionally attributed to the central nervous system, glucose sensing by the portohepatic region is now known to play an important role in modulating the response to hypoglycemia That glucosensors reside in the splanchnic region has been known for some time (5) (6) (7) (8) (9) (10) , and the requisite neural circuitry (i.e., afferent and efferent limbs) for a portohepatic-sympathetic loop has been identified (8, 9) . Our own work suggests that the portohepatic glucosensors are important mediators of the sympathetic response to hypoglycemia (10, 11) . Further, under conditions of progressive hypoglycemia, as is seen in many clinical situations, these portohepatic glucosensors may be the most important regulators of this sympathetic response (11) .
The portohepatic glucosensors have generally been presumed to reside within the liver (5, 7, 9, 10, 12) . Afferent nerve terminals have been located in the proximity of the hepatocytes (12, 13) , and efferent innervation of the liver has been well established (9, 12) . However, fine varicose terminals of the hepatic vagus nerve have been observed in the adventitia of the portal vein (14) (15) (16) , raising the possibility of a portal locus for the glucosensors. To ascertain whether those glucosensors essential to modulation of the sympathetic response in hypoglycemia reside in the portal vein, as opposed to the liver, we used a variation of the local glucose irrigation technique in which liver glycemia is normalized in the presence of general systemic hypoglycemia (10, 11) . In this variation, placement of the portal vein cannula was adjusted so as to normalize either liver glycemia alone or both portal vein and liver glycemia. Results indicated that portal vein, not liver, glucose concentration determines the sym- pathoadrenal response, a finding consistent with a portal vein glucosensor locus.
RESEARCH DESIGN AND METHODS
Animals and surgical procedures. Experiments were conducted on male Wistar rats (weight 284 ± 10 g, n = 22) in the conscious relaxed state. All surgical and experimental procedures were preapproved by the University of Southern California Institutional Animal Care and Use Committee.
One week prior to experiments, animals were chronically cannulated under single-dose anesthesia (3:3:1 ketamine HC1, xylazine, acepromazine maleate; 0.10 cm 3 /100 g body wt, given intramuscularly). Cannulas were placed in the portal vein (silastic, 0.03 cm internal diameter [ID] ) for glucose infusion during liver irrigation, in the carotid artery (Clay Adams, PE-50) for arterial blood sampling, and in the jugular vein (dual cannula silastic, 0.012 cm ID) for peripheral infusion (PER) of insulin and glucose. The portal vein cannula was placed either adjacent to (PORADJ, 0.6 ±0.1 cm) or upstream from (POR^, 2.7 ±0.1 cm) the liver. All cannulas were tunneled subcutaneously and exteriorized at the back of the neck and encased in silastic tubing (0.18 cm ID) sutured to the skin. Study design. Animals were allowed 5 days' recovery from surgery to regain body weight. Three days after surgery, 300 ul of blood was drawn and analyzed for plasma alanine aminotransferase (ALT) activity, a sensitive measure of hepatocellular integrity. There were no significant differences in ALT activity between animals portally cannulated (PER, POR^, PORupg) and those littermates randomly assigned to the blood donor group with only a carotid cannula (18.9 ± 3.0 vs. 16.5 ± 2.4 U/l, respectively). Twenty-four hours before the experiment, all food was removed from the cage. Hyperinsulinemic-hypoglycemic clamp. All animals were exposed to the same general protocol for the induction of hypoglycemia. Before the experiment, animals were placed in a modified metabolic chamber and allowed to rest for 30 min (-60 to -30 min). Basal samples were drawn at -30 and 0 min for analysis of glucose and catecholamines. At 0 min, after arterial sampling, insulin (50 mU • kg" 1 • min"') and glucose infusions (variable) were initiated and maintained for 105 min of the hypoglycemic clamp. Serial sampling for glucose was performed at 10-min intervals until deep hypoglycemia was attained at 60 min, so as to maintain the integrity of the hypoglycemic clamp and control the rate of fall in blood glucose. Deep hypoglycemia (-2.5 mmol/1) was achieved by 60 min and was sustained for the remaining 45 min of the experiment (60-105 min). Arterial catecholamine and glucose samples were taken at 60, 75,90, and 105 min of deep hypoglycemia Experimental design. Each animal participated in one of three specific experimental conditions distinguished by the site of glucose infusion (Fig. 1) . Figure L4 represents peripheral glucose infusion (PER) via the jugular vein. This protocol effectively served as the experimental control group in which whole-body hypoglycemia was induced. Figure LB represents the portal vein upstream (PORyps) experimental condition whereby portal and liver glucose concentrations were normalized during systemic hypoglycemia Figure W represents glucose infusion via the portal vein adjacent to the liver (POR^) whereby the cannula was advanced to the liver, thus normalizing only the liver glucose concentrations while the portal vein and periphery remained hypoglycemic. According to the working hypothesis, if the sensors reside exclusively in the portal vein, then portal vein concentrations will dictate the sympathoadrenal response irrespective of liver glycemia Calculations. The estimated liver glucose concentration (GJ was calculated as G L = G A + (GrNF roR /HPF), where G A is the arterial glucose concentration (in micromoles per miUiliter), GINFpo R is the portal glucose infusion rate (in micromoles per minute), and HPF is the hepatic plasma flow rate (in milliliters per minute). The estimated portal vein glucose concentration (Gpy) was calculated as Gpy = G A + (GINFpQ RUPS / PVPF), where GINFpo RUPS is the upstream portal glucose infusion rate (in micromoles per minute) and PVPF is the portal vein plasma flow rate (in milliliters per minute). Hepatic plasma flow was estimated to be 1.3 ml • g" 1 liver • min" 1 • liver wt (g), and the portal vein flow rate was assumed to be 80% of the hepatic plasma flow rate (17, 18) . Because experiments were preceded by a 24-h fast, portal vein and hepatic glycemias were assumed equal to the arterial glucose concentration in the absence of any portal glucose infusion. Due to cannula placement during P O R^ (advanced to the liver), portal glycemia was assumed to be equal to arterial glucose concentration. Analytical procedures. Glucose was assayed by the glucose oxidase method (YSI, Yellow Springs, OH). Epinephrine and norepinephrine concentrations were assayed using a single-isotope radioenzymatic approach (19) . Basal insulin samples were assayed via a radioimmunoassay (RIA) kit (Iinco Research, St. Charles, MO), and steady-state hyperinsulinemic samples were assayed using an RIA according to Herbert et al. (20) . ALT was assayed spectrophotometrically (21) . Data analysis. The results are expressed as means ± SE. Comparisons of animal characteristics between groups were made using one-way analysis of variance (ANOVA) for independent groups. Comparisons between treatments over time were made by repeated-measures ANOVA using Tukey's test for post hoc comparisons. Significance was set at P < 0.05.
RESULTS
For all experimental protocols, arterial insulin concentrations increased from a mean basal value of 61 ± 6 pmol/1 to a hyperinsulinemic plateau of 9,372 ± 1,798 pmol/1. No significant differences were observed between protocols with respect to basal or elevated insulin concentrations. Basal arterial glucose concentrations (7.2 ± 0.3 mmol/l) were not significantly different between protocols. By design, there were no significant differences in arterial glucose concentrations during deep sustained hypoglycemia (2.4 ±0.1 mmol/1; P = 0.80) among the three glucose infusion protocols. Hepatic glycemia was also allowed to decrease to a deep hypoglycemic level of 2.3 ± 0.2 mmol/1 during PER (Fig. 2) . In contrast, hepatic glycemia remained elevated in the normal range during both liver irrigation protocols, POR^j and PORypg (Fig. 2) mmol/1 between 60 and 105 min of the hypoglycemic clamp. In response to whole-body hypoglycemia (PER), arterial epinephrine concentrations increased 16-fold, from basal 3.0 ± 0.6 nmol/1 to a mean of 46.4 ± 4.3 nmol/1 by 105 min (Fig. 3) . Infusing glucose into the liver only, reestablishing hepatic euglycemia had no effect on the maximal epinephrine response (42.0 ± 3.4 nmol/1; P = 0.73). However, during PORyps, when both the portal vein and liver were maintained normoglycemic, there was a 67% suppression in the epinephrine response when compared with either PER or POR^j (P < 0.001 for both).
Although the norepinephrine response was less dramatic than the epinephrine response, 2.7-vs. 16-fold above basal for PER, a similar pattern was observed between protocols. In response to whole-body hypoglycemia (PER), norepinephrine increased from 4.0 ± 1.8 to 10.9 ± 1.4 nmol/1 (Fig. 3) . During POR^j, norepinephrine levels increased to 10.3 ± 1.3 nmol/1, not significantly different from those during PER (P = 0.84). By comparison, there was a significant suppression in the norepinephrine concentration for POR UPS (7.6 ± 1.0 nmol/1) when compared with PER and PORAOJ during the final sampling interval (P = 0.035). DISCUSSION The current findings demonstrate that the magnitude of the sympathoadrenal response to hypoglycemia is dictated by the blood glucose concentration present in the portal vein, not by that in the liver. Clamping arterial blood glucose concentrations ensured that all tissues, except the portohepatis, were exposed to identical levels of glucose during the three experimental protocols: PER, POR UPS , and POR^j. When the liver and portal vein were allowed to become hypoglycemic along with the rest of the body, we observed a full-blown sympathetic response that included a 16-fold increase in epinephrine and ~3-fold increase in norepinephrine. A similar fullblown sympathetic response was observed when liver glycemia, but not portal glycemia, was normalized (POR^j). In sharp contrast, a significant suppression of the sympathoadrenal response to hypoglycemia (67% for epinephrine and 50% for norepinephrine) was observed when the blood glucose concentrations for both the portal vein and the liver were normalized (POR UPS ). Because the only difference between POR^ and POR^ was the concentration of glucose in the portal vein, our findings demonstrate a portal vein locus for those glucosensors that mediate the sympathetic response to hypoglycemia.
There is substantial neurophysiological data supporting a portal vein locus for the glucosensors associated with glucoregulation. The portohepatic region is known to be innervated by afferent fibers sensitive to changes in metabolite concentrations, pressure, and osmolarity (8, 9, 22) . Using fluorescent staining techniques, it has been determined that hepatic vagal afferents, believed to be associated with these portal glucosensors, terminate predominantly in the portal vein (16) . Glucose-sensitive afferents, localized to the portal region, have been found to possess firing rates inversely proportional to the portal vein glucose concentration (5,7). Glucose injections into the portal vein have also been shown to influence neuronal activity in both the ventromedial and the lateral hypothalamus (6, 23) . Shimizu et al. (23) further demonstrated that the majority of identifiable glucose-sensitive neurons within the lateral hypothalamus were responsive to changes in portal blood glucose concentration. Similar observations have been forthcoming for the nuclear tractus solitarius, where the glucose-sensitive neurons were shown to be sensitive to elevations in portal glycemia (24) . That these portal glucose-sensitive afferents are part of a portalsympathetic glucoregulatory reflex has been proposed by several investigators (9, 22, 24) . Sympathetic output from the ventromedial hypothalamus and its influence on glucose metabolism has been well characterized (9) . Additionally, the discharge rate from the adrenal and splanchnic efferents has been shown to be depressed by elevations in portal glucose concentration (7). The current findings provide in vivo evidence in support of a functional portal-sympathetic glucoregulatory reflex.
While our previous reports have focused on the importance of the hepatic glucosensors, those findings are in fact consistent with current observations, hi those previous studies on dogs, portal cannulation was effected upstream from the liver. As such, both portal and liver glycemia were normalized during portal glucose infusions. While we had presumed the glucosensors to reside in the liver, our protocols did not exclude the possibility of a portal vein locus. That is, our previous protocols had only restricted critical glucosensors to the portohepatic region. Given that our current study was conducted on a different species, rat versus dog, the findings are surprisingly consistent with our previous observations and may be viewed as general. The magnitudes of the epinephrine (16-fold increase) and norepinephrine (3-fold increase) responses under uniform deep hypoglycemia (PER) were comparable to those observed for dogs under similar conditions (11, 25) . Also, the degree of suppression in the sympathetic response to hypoglycemia achieved with portal normoglycemia (-50-70%) appears comparable for both species (11, 25) .
hi summary, the current study demonstrates a portal vein, not a liver, locus for those splanchnic glucosensors critical to modulating the sympathoadrenal response to hypoglycemia. While these observations do not exclude other potential glucosensing loci (e.g., the brain), they do suggest a predominant role for the portal glucosensors in controlling sympathetic output, hi this respect, our current findings in rats are quantitatively consistent with our previous findings in dogs. That similar observations have been forthcoming for two different mammalian species greatly increases the probability that portal glucosensors are critical for glucoregulation in other species, including humans.
